Research Article

Differentiating COVID-19 and dengue from other febrile illnesses in co-epidemics: Development and internal validation of COVIDENGUE scores

Patrick Gérardin[1], Olivier Maillard[1], Léa Bruneau[2], Frédéric Accot[3], Florian Legrand[3,5], Patrice Poubeau[3,4,5], Rodolphe Manaquin[3,4,5], Fanny Andry[3,4,5†], Antoine Bertolotti[1,3,4†], Cécile Levin[3,4,5]

[1] Centre for Clinical Investigation - Clinical Epidemiology (CIC 1410), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de la Réunion, Saint Pierre, Reunion, France

[2] Department of Public health and Research Support, Centre Hospitalier Universitaire de la Réunion, Saint Denis, Reunion, France

[3] COVID-19 testing centre, Centre Hospitalier Universitaire de la Réunion, Saint Pierre, Reunion, France

[4] Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de la Réunion, Saint Pierre, Reunion, France

[5] City to Hospital Outpatient Clinic for the care of COVID-19, Centre Hospitalier Universitaire de la Réunion, Saint Pierre, Reunion, France

Corresponding Author: P. Gérardin, Center for Clinical Investigation (CIC1410), CHU Réunion, BP 350, 97448 Saint-Pierre Cedex – Reunion, (patrick.gerardin@chu-reunion.fr)

[†] Contributed equally.

Short running head title: **Scores to distinguish COVID-19 from dengue and other febrile illnesses in co-epidemics**

Abstract

Background. In a retrospective cohort study, we previously distinguished the factors associated with coronavirus 2019 (COVID-19) or dengue from those associated with other febrile illnesses (OFIs). In this study, we developed a scoring system to discriminate both infectious diseases.

Methods. Predictors of both infections were sought using multinomial logistic regression models (OFIs as controls) in all subjects suspected of COVID-19 who attended the SARS-CoV-2 testing center of Saint-Pierre teaching hospital, Reunion Island, between March 23 and May 10, 2020. Two COVIDENGUE scores were developed and internally validated by bootstrapping for predicting each infection after weighting the odd ratios according to a predefined rule. The discriminative ability of each score was assessed using the area under the receiver operating characteristic curve (AUC). Their calibration was assessed using goodness-of-fit statistics.

Results. Over 49 days, 80 COVID-19, 60 non-severe dengue and 872 OFI cases were diagnosed. The translation of the best fit model yielded two COVIDENGUE scores composed of 11 criteria: contact with a COVID-19 positive case (+3 points for COVID-19; 0 point for dengue), return from travel abroad within 15 days (+3/-1), previous individual episode of dengue (+1/+3), active smoking (-3/0), body ache (0/+5), cough (0/-2), upper respiratory tract infection symptoms (-1/-1), anosmia (+7/-1), headache (0/+5), retro-orbital pain (-1/+5), and delayed presentation (>3 days) to hospital (+1/0). The AUC was of 0.79 (95%CI 0.76-0.82) for COVID-19 score and of 0.88 (95%CI 0.85-0.90) for dengue score. Calibration was satisfactory for COVID-19 score and excellent for dengue score. For predicting COVID-19, sensitivity was of 97% at the 0-point cut-off and specificity approximated 99% at the 10-point cut-off. For predicting dengue, sensitivity approximated 97% at the 3-point cut-off and specificity 98% at the 11-point cut-off.

Conclusions. In conclusion, the COVIDENGUE scores proved discriminant to differentiate COVID-19 and dengue from other febrile illnesses in the context of SARS-CoV-2 testing center during a co-epidemic. Further studies are needed to validate or refine these scores in other settings.

Author Summary

In the last two years, several countries not only have faced the impact of the coronavirus 2019 (COVID-19) but also dengue epidemics simultaneously, evoking an overburden to healthcare systems. On Reunion Island, southwestern Indian ocean, dengue virus is circulating since 2004 under an endemo-epidemic pattern with outbreaks peaking between March and May and has prominently intensified annually since 2015. Regarding COVID-19, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) emerged in March 2020 and was brought from the Bahamas to the island. COVID-19 and dengue have been deemed clinically similar, especially within the first two days from symptom onset. In the framework of a cohort study conducted at a SARS-CoV-2 testing center between March 23 and May 10, 2020, we developed two scores aimed at predicting both infections. The discriminative ability (the ability to diagnose each infection) was satisfactory to good for COVID-19 (area under receiver operating characteristic curve [AUC] 0.79, 95% confidence interval [CI] 0.76-0.82) and good for dengue (AUC 0.88, 95%CI 0.85-0.90). The calibration (the adequacy between predicted and observed infections) was satisfactory for both scores. Each score was user-friendly and provided an easy guidance for predictive analysis, whether in strategies maximizing the prediction or the exclusion of each infection.

Keywords: coronavirus; COVID-19; severe acute respiratory syndrome; SARS-CoV-2; dengue; arbovirus; flavivirus; epidemics; pandemics; cohort study; risk factors; multivariate analysis; logistic regression; multinomial logistic regression; prediction model; score

Background

Prompt identification and management of overlapping COVID-19 and dengue infections may prevent cases of both viral diseases from deteriorating [1]. Moreover, it can avoid events of hospitalization in the Intensive Care Unit (ICU) and nosocomial transmission of both infections which may be useful whenever syndemics stress healthcare systems [2]. For public health, more rapid quarantine, contact tracing and vector control measures may help to mitigate the dynamics of both epidemics [2,3].

Since Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spread globally, several countries have been facing dengue epidemics with the fear of increased mortality in the most vulnerable populations [4]. Moreover, the absence of both highly sensitive and specific rapid diagnostics tests may have hampered discrimination between the two separate diagnoses possibly leading to misdiagnoses and the implementation of inadequate countermeasures in emergency situations [4]. On Reunion Island, a French overseas territory located in the southwestern Indian ocean region known to have host one of the largest chikungunya outbreaks [5], dengue virus (DENV) is endemic with annual epidemics occurring since 2015 [6]. Moreover COVID-19, which emerged in March 2020, has established an autochthonous transmission since August 2020 [7].

Surprisingly, most prediction models in the field of COVID-19 research have been dedicated to prognosis and not to the identification of people diseased from infection nor at risk of being infected [8]. Given that differential diagnosis between COVID-19 and dengue was difficult, we set-up a cohort study and developed a multinomial logistic regression model (MLR) aimed at distinguishing SARS-CoV-2 or DENV infections from other febrile illnesses (OFIs) during the first COVID-19 introductive pandemic wave [9].

Herein, we furthered our previous reflection to improve the predictive capability of our model in testing the hypothesis that the more variables included in the model, the better the discrimination between the diseases [10].

The objective of this study was to develop and internally validate a scoring system able to predict both infectious diseases which to date had never been performed.

Methods

Study design, study setting and population

A retrospective cohort study was conducted using prospectively collected data between 23 March and 10 May 2020, on all participants screened for COVID-19 within the UDACS (*Unité de Dépistage Ambulatoire du COVID-19 Sud*) of Saint-Pierre which is one of the two SARS-CoV-2 testing centers of the *Centre Hospitalier Universitaire Réunion* (CHU Reunion) providing care for the general population at the time. People without symptoms or with co-infections were excluded from the study.

Consecutively arriving outpatients to the SARS-CoV-2 testing center were informed of the study both verbally and by means of an informational document. Adults, as well as children under the age of 18 years (having the additional verbal consent of their parent or legal guardian) who expressed no opposition were asked to answer a questionnaire and were personally interviewed by a nurse in accordance with the French legislation on bioethics for retrospective research.

Patients' medical records were retrospectively reviewed and anonymized data were collected in standardized forms according to the MR-004 procedure of the *Commission Nationale de l'Informatique et des Libertés* (the French Information Protection Commission). The ethical character of this study on previously collected data was approved by the Scientific Committee for COVID-19 research of CHU Reunion and anonymized data were registered on the Health Data Hub (N° F20201021104344/October, 2020).

Data collection and gold standard procedure

The questionnaire included information on: i) demographics (gender and age), ii) occupation, iii) risk factors (smoking, obesity, return from travel abroad during the 15 previous days), iv) comorbidities (diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, cancer, previous episode of dengue and "other comorbidities"), v) intra-household and individual exposure to SARS-CoV-2, vi) individual symptoms (fever, cough, dyspnea/shortness of breath, body aches, diarrhea, gut symptoms, ageusia, metallic taste, anosmia, fatigue, headache, retro-orbital pain and

129 upper respiratory tract infection symptoms) and vii) treatment (antihypertensive drugs and/or
130 hydroxychloroquine). Patients' temperature, pulse rate, respiratory rate, and oxygen saturation
131 (SpO_2) were also measured during the consultation, as well as the presence of cough and/or anxiety.
132 People reporting symptoms were examined by a medical resident or a senior infectious disease
133 specialist in accordance with routine care procedures.

134 All participants were screened for COVID-19 by a nurse using a nasopharyngeal swab for 20
135 seconds in one nostril [11]. Each sample was administered for a SARS-CoV-2 reverse transcription-
136 polymerase chain reaction (RT-PCR) using the Allplex 2019-nCov™ assay (Seegene, Seoul, Republic of
137 Korea) or an in-house kit (CNR Pasteur) targeting N, RdRP and E genes, or N and IP2/IP4 targets of
138 RdRP depending on which assay was used. Moreover, each participant of the study that was
139 suspected of having dengue was tested for NS1 antigen using an OnSite™ Duo dengue Ag-IgG-IgM
140 rapid diagnostic test (CTK Biotech, San Diego, CA, USA). If these patients had a negative result, they
141 were explored further with a DENV RT-PCR or a dengue serology panel according to the timing of
142 symptoms.

143

144 ***Statistical analysis***

145 Proportions between COVID-19, dengue, and non-COVID-19 non-dengue OFI patients were
146 compared using Chi square or Fisher exact tests, where deemed appropriate. Bivariable and
147 multivariable multinomial logistic regression (MLR) models were fitted within Stata14® (Statacorp,
148 College Station, Texas, USA) to identify independent predictors of COVID-19 and dengue using OFIs
149 as controls.

150 The first step of the process included fitting a full MLR model with all significant covariates
151 identified by bivariable analysis [9]. From the candidate predictors, we used a backward stepwise
152 selection procedure to drop out non-significant variables (output if $P>0.05$). At this second step, we
153 built a parsimonious MLR model with all significant predictors. In this model, an adaption of the
154 Hosmer-Lemeshow goodness-of-fit chi2 test was used for MLR models with polytomous categorical

155 outcomes [12] (hereafter named MHL test for multinomial Hosmer-Lemeshow) to minimize the
156 discrepancy between predicted and observed events. In these analyses, crude, and adjusted odds
157 ratios (OR) and 95% confidence intervals (95% CI) were assessed using the binomial and Cornfield
158 methods respectively.

159 Based on the assumption that if there are more variables, there will be better discrimination
160 [10], we added variables that were ruled out at the borderline of significance during the backward
161 stepwise elimination process to our previous 9-covariate parsimonious model [9].

162 The strategy of this third step is detailed in the text file S1.

163 Weighted analyses on the overall inverse probability of hospitalization to assess the potential
164 for selection bias and to test the robustness of the identified predictors were performed next.

165 Lastly, from the best fit MLR compromise model, we derived two simple scores, the
166 COVIDENGUE scores (one for COVID-19 and, one for dengue) after weighting the OR according to a
167 predefined rule (S1 Table). This rule gave a weight to all the model covariates (no matter their
168 significance) to maximize the possible combinations and to provide the largest range of values which,
169 theoretically, enables the best discrimination.

170 The discriminative ability of the models and of the COVIDENGUE scores (*i.e.,* the model and
171 score performances) for the diagnosis of COVID-19 and dengue were tested using receiver operating
172 characteristic (ROC) plot analyses which considers ROC plots and areas under ROC curves (AUC) with
173 their 95%CIs [13]. Discrimination is usually considered as null when the AUC is 0.5, poor when
174 between 0.5 and 0.7, satisfactory between 0.7 and 0.8, good between 0.8 and 0.9, excellent between
175 0.9 and 1, and perfect when the AUC equals 1. In addition, we provided classification plots to assess
176 the discriminative ability of COVIDENGUE scores conditional to absolute risk thresholds [14]. Finally,
177 scores performances were internally validated by using bootstrapping (2000 replicates).

178 The calibration of the COVIDENGUE scores (*i.e.*, the adequacy between predicted and
179 observed events) was evaluated using state-of-art calibration plots [15] and Hosmer-Lemeshow tests

180 for MLR and binomial logistic regression models [12,16], as well as with event-based or risk-based
181 calibration plots which were displayed over the range of MHL deciles of predicted risks.

182 The diagnostic performance of each COVIDENGUE score cut-off was displayed in terms of
183 sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR-), positive
184 predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy.

185 For all these analyses, observations with missing data were ruled out, tests were two-tailed,
186 and a *P*-value less than 0.05 was considered as statistically significant.

187 The full details of the methods can be found in the text file S1. The results were reported
188 following both the STROBE and TRIPOD reporting guidelines for observational studies and prediction
189 models (text file S2), respectively [17,18].

190 ## Results

191 ***Characteristics of the study population***

192 Between 23 March and 10 May 2020, 1,715 subjects were admitted to the UDACS for screening for
193 or diagnosis of COVID-19. Over this 6-week period, the lab did not diagnose any cocirculation of
194 influenza or non-influenza respiratory viruses.

195 As part of an expanded screening week dedicated to all admissions to our hospital, 370
196 subjects who were screened opportunistically and 332 fully asymptomatic subjects were ruled out
197 leaving 1,013 outpatients eligible for this analysis. The study population is shown in Figure 1.
198 The characteristics of the 1,013 of patients who consulted the COVID-19 screening center during the
199 COVID-19 dengue co-epidemics are presented in S2 Table.

200 COVID-19 was diagnosed in 80 patients (7.9%) and dengue in 61 patients (6.0%) while 872
201 patients tested negative and were clinically considered as non-COVID-19, non-dengue subjects.
202 Interestingly, COVID-19 patients presented themselves later in the course of the illness compared to
203 patients with dengue or OFIs (time elapsed since symptom onset, 7.5 days versus 4.2 days or 6.3
204 days, $P<0.001$). Dengue was more likely to be symptomatic than COVID-19 as exemplified by higher
205 frequencies of fever, body ache, gut symptoms, fatigue, headache, and retro-orbital pain, as well as a
206 higher need for physical examination. However, COVID-19 exhibited longer durations of fatigue and
207 rhinorrhea.

208

209 **Bivariate and multivariate analyses**

210 The crude relationships between the sociodemographic, epidemiological, and clinical characteristics
211 in cases of COVID-19, dengue and OFIs are presented in S3 Table.

212 Bivariable analysis identified anosmia, the return from travel abroad during the previous 15
213 days, contact with a COVID-19 positive case and delayed presentation (beyond three days since
214 symptom onset) as candidate predictors for COVID-19, whereas healthcare workers and active
215 smokers as those protected against COVID-19. Headache, retro-orbital pain, body ache, fatigue, gut

216 symptoms, and previous individual episode of dengue were potential predictors for dengue, while
217 the recent return from travel abroad and cough were potential protective factors against dengue.
218 Interestingly, Upper Respiratory Tract Infection (URTI) symptoms provided protection against both
219 infections (which means they were associated with OFIs), while the role of fever and ageusia was less
220 clear, these being associated with both diagnoses of interest (S3 Table).

221 The variables that were significant in the bivariable analysis were entered into a full
222 multivariable MLR model (S4 Table). This generated 4% of missing observations (n=46). It supported
223 the role of anosmia, contact with a COVID-19 positive case and recent return from travel abroad as
224 independent predictors of COVID-19 as well as an association of active smokers to protection against
225 COVID-19. In turn, previous individual episodes of dengue, body ache, headache and retro-orbital
226 pain were independent predictors of dengue, while cough was less likely to be observed with this
227 infection. As for the bivariable analysis, URTI symptoms were indicative of OFIs. Alternatively, fever
228 proved non discriminant even though it was far more common with dengue which motivated its
229 exclusion from further analyses. As in our previous analysis [9], these findings were contrasted by the
230 weighting on the inverse probability of hospitalization rates (S5 Table).

231 After multicollinearity analysis, control of overfitting and unnecessary adjustments, the best fit
232 MLR compromise model (based on AIC and BIC metrics) included eleven covariates (Table 1). This
233 confirmed the role of anosmia, contact with a COVID-19 positive case and/or recent return from
234 travel abroad as independent predictors of COVID-19, as well as the role of body ache, headache,
235 previous individual episode of dengue and retro-orbital pain as predictors of dengue. Conversely, in
236 this model, active smoking, cough, and URTI symptoms were considered as protective factors against
237 COVID-19, dengue, or both.

238 Goodness-of-fit and discrimination indicators of the MLR models are displayed in S6 Table. We
239 made the assumption that the best fit compromise model could be achieved with the eleven
240 abovementioned covariates. The AUCs of the model were of 0.80 (95%CI 0.74-0.86) for COVID-19
241 and 0.89 (95%CI 0.84-0.92) for dengue in the primary analysis (Figure 2, panel a), and of 0.80 (95%CI

242 0.73-0.86) and 0.88 (95%CI 0.84-0.92) after bootstrapping, respectively. Further adjustment on both
243 age and/or gender did not improve the AUC of the model to a point sufficient enough to change
244 interpretation when considering AUC boundaries (S6 Table).
245
246 ***Score development and internal validation***
247 Based on this final model, we derived two COVIDENGUE scores. For a better appropriation, we
248 decided to set the weight of each dengue clinical criterion at 5 points. With this exception, the
249 weighting scale was as described in S1 Table.
250 The translation of the final MLR model into two COVIDENGUE scores was satisfactory. This step
251 showed barely a 1-point loss in the discriminative ability for both COVID-19 and dengue and a
252 superimposition of model and score ROC plots (Figure 2, panel b and panel c).
253 The median value of the COVID-19 score was 1 (Q_1-Q_3: 0 to 3, range: -4 to 14) and the median
254 value of the dengue score was 3 (Q_1-Q_3: -1 to 7, range: -4 to 18). In the primary analysis, the
255 discriminative ability of the scores was satisfactory to good for COVID-19 (AUC 0.79, 95%CI 0.76-0.82)
256 and good for dengue (AUC 0.88, 95%CI 0.85-0.90) (Figure 2, panel d). Interestingly, the dengue score
257 exhibited higher true positive rates than the COVID-19 score (which means false negative cost was
258 minimized versus the false positive cost) in risk thresholds higher than 0.4. COVID-19 had higher
259 false positive rates in risk thresholds under 0.5 than the dengue scores (which means FP cost was
260 minimized versus FN) (S1 Fig.).
261 After bootstrapping, when considering confidence intervals, the discriminative ability was
262 between poor and good for COVID-19 (AUC 0.75, 95%CI 0.68-0.82) and good for dengue (AUC 0.86,
263 95%CI 0.81-0.90), which represented an AUC loss of five points and three points from the final MLR
264 model, respectively.
265 Overall, the calibration of the COVIDENGUE scores as shown by calibration plots (S1 Fig.) and
266 MHL tests (S7 Table and S8 Table) was deemed satisfactory albeit prone to underfitting for COVID-19
267 (slope: 1.22, intercept 0.08; chi2 (6) 1.75, P=0.9416), whereas it was excellent and consensual for

268 dengue (slope: 0.97, intercept 0.12; chi2 (8) 6.78, *P*=0.5605). Strikingly, despite few discrepancies
269 between predicted and observed events (S2 Fig. and S3 Fig., panel a and panel c), and a trend
270 towards underprediction of COVID-19 events (S4 Fig., panel a), the MHL test of both COVIDENGUE
271 scores was well balanced across the deciles of predicted risks (S7 Table and S8 Table) and their
272 calibration displayed other metrics better than those of the reference model (S9 Table).

273 For overall COVID-19 prediction, a threshold of 0 points displayed a sensitivity of 97.3% (95%CI
274 96.2%-98.3%) and a NPV of 99.0% (95%CI 98.4%-99.6%), while a threshold of 10 points displayed a
275 specificity of 98.8% (95%CI 98.1%-99.5%) and a PPV of 65.1% (95%CI 62.1%-68.1%). A 3-point cut-off
276 maximized both sensitivity and specificity (78.1% and 63.7%, respectively). Regardless of COVID-19
277 prevalence, the COVID-19 score was effective in excluding COVID-19 (LR- <0.10) for negative score
278 values under -1, whereas it was effective for diagnosing COVID-19 (LR+ >10) with score values higher
279 than 7. The detailed performances of the COVID-19 score are presented in S10 Table, its intrinsic and
280 extrinsic properties in Figure 3 (Panel a to panel d). For COVID-19 individual risk prediction, the
281 estimated probability of being infected derived from the COVID-19 score was $Prob_{(Y=1/x)} = 1 / (1 + exp^{-}$
282 $^{(-3.698086 + 0.3533028 X score value)})$.

283 For dengue overall prediction, a threshold of 3 points displayed a sensitivity of 96.7% (95%CI
284 95.5%-97.8%) and a NPV of 99.7% (95%CI 99.4%-100%) while a threshold of 11 points displayed a
285 specificity of 97.7% (95%CI 96.7%-98.6%) and PPV of 40.3% (95%CI 37.2%-43.3%). A 6-point cut-off
286 maximized both sensitivity and specificity (83.3% and 71.7%, respectively). Regardless of dengue
287 prevalence, the dengue score was effective in excluding dengue (LR- <0.10) for score values under 4,
288 whereas it was effective for diagnosing dengue (LR+ >10) with score values higher than 10. The
289 detailed performances of the dengue score are presented in S11 Table, its intrinsic and extrinsic
290 properties in Figure 3 (Panel a to panel d). For dengue individual risk prediction, the estimated
291 probability of being infected derived from the dengue score was $Prob_{(Y=1/x)} = 1 / (1 + exp^{-(-5.508826 +}$
292 $^{0.4406125 X score value)})$.

293 ## Discussion

294 In this study, COVIDENGUE scores were developed and internally validated. An eleven covariate-
295 based prediction model aimed at distinguishing COVID-19 from dengue and other febrile illnesses at
296 their clinical onset was made in the context of cocirculation of SARS-CoV-2 and DENV. Overall, the
297 predictive performance of the score, meaning the ability to diagnose or to rule out infection, was
298 good for dengue and satisfactory for COVID-19, while calibration performance meaning the ability to
299 minimize the discrepancy between expected and observed events, was at least satisfactory on
300 multiple metrics of goodness-of-fit statistics. The dengue score for which symptoms were good
301 predictors, displayed both better sensitivity and a higher negative predictive value while the COVID-
302 19 score for which risk factors were paramount, proved more specific and had a higher positive
303 predictive value across the whole range of cut-offs.

304

305 **Strengths and limitations**

306 A scoring system should have both construct and content validity. It must be able to be reproduced
307 over time and across geographic and methodological boundaries. It must also be accurate
308 (calibration and discrimination) and clinically meaningful [19]. Before this study, we previously
309 assumed that COVID-19 and dengue diagnoses could be affected by a misclassification bias which
310 could stem from the poor sensitivity of both SARS-CoV-2 molecular and DENV NS1 antigen tests
311 rather than from their false positives [9]. This putative bias was believed to be minimal given that,
312 firstly, on Reunion Island, like anywhere else during the rise of the COVID-19 pandemic [20], there
313 was little cocirculation of other respiratory viruses that could have competed with SARS-CoV-2 and
314 caused false negatives, [21] and secondly, for COVID-19, negative samples were retested by RT-PCR
315 upon onset of new symptoms, meaning that rapid antibody or antigenic tests were ruled out, while
316 for dengue, the workup was completed by a RT-PCR or a serology test to downsize false negative and
317 false positive proportions [22-24]. This caution decision rule likely pledges the diagnostic accuracy of
318 our gold standards.

319 Interestingly, the calibration of both scores was satisfactory to excellent and displayed
320 measures close to the theoretical model from which they were derived based on a set of various
321 goodness-of-fit metrics. Notwithstanding a relatively small study population, the diagnostic accuracy
322 of gold standards, along with the acceptable calibration properties ensure the validity of construct of
323 the COVIDENGUE scores and the reliability of their predictions at the individual level for the dengue
324 score, while, together with their discriminative ability, also lend support to their clinical utility [25].

325 The COVIDENGUE scores were developed using MLR [9] which is the gold standard method for
326 assessing non-ordered polytomous categorical outcomes [26,27]. Except for active smoking whose
327 protective effect against SARS-CoV-2 infection remains a matter of debate among researchers
328 [28,29], all predictors retained to build the scores had been previously identified as relevant
329 indicators of COVID-19 or dengue or associated with OFIs (especially respiratory infections) [29-40]
330 This ensures both the validity of content of this scoring system and the possibility of contrasted
331 predictions. For example, international travel had been identified as a source of COVID-19 during the
332 first pandemic wave [34,35]. In a recent Colombian study [38], dengue proved more symptomatic
333 than COVID-19 and dengue patients came to the hospital in greater numbers than COVID-19
334 patients. In Brazil's Amazonian basin, prior to a dengue infection, as diagnosed by positive IgG
335 antibodies was associated with twice the risk of clinically apparent COVID-19 [36]. The external
336 validity of the other predictors has been discussed thoroughly in our previous study [9]. Interestingly,
337 similar to our first analysis, weighting on the inverse odds of hospitalization abrogated the
338 significance of a few predictors (Table 1 *versus* S5 Table), which suggests a contrast in our findings at
339 the population level and motivates further validation studies in the primary care setting.

340 Notably, this hospital-based study was conducted in a SARS-CoV-2 screening center which may
341 have underestimated the real incidence of dengue and introduced another information bias in that
342 dengue patients could have been potentially directed towards other units or even underreported
343 given the lack of epidemiological predictors reported for dengue [9]. This potential limitation of the
344 validity of content should be investigated in future studies by adding more risk factors for dengue to

345 refine our models. Lastly, our scoring system was composed of only clinical and epidemiological
346 criteria. It was user-friendly for diagnosis purposes which should facilitate its utilization across
347 different settings while also helping its external validation.
348
349 **Interpretation**
350 For epidemiological and clinical practices, the overall performance of a prediction model relies first
351 on its discrimination [13]. In this perspective, ROC plots do not offer more information than the AUC
352 to indicate the discriminative ability [13,14]. In this study, we demonstrated that the discriminative
353 ability of the models could be improved only at the unreasonable cost of complexity (20-item model),
354 or when adding age to the COVID-19 model; a factor whose effect might change according to the
355 context (S6 Table). This study also showed that the translation of the model into two scores was not
356 accompanied by a significant loss in discriminative ability (Figure 2) which suggests an adequate
357 weighting of the scores.
358 Importantly, we provided classification plots which may offer more information for decision-
359 making conditional to risk thresholds [13,14]. Overall, classification plots may reveal a better ability
360 of the COVID-19 score to predict non-events (OFIs) and a better ability of dengue score to predict
361 events (dengue). Moreover, at lower risk thresholds the COVID-19 score exhibited a lower cost of FP
362 than the dengue score. For example, when the event risk was 0.2, the COVID-19 score yielded a 0.5:1
363 FN to FP ratio while it was 1:1 for the dengue score (Figure S1). These results aligned with a trend
364 towards a better specificity for the COVID-19 score than for the dengue score across the range of cut-
365 off values (Figure 3). Conversely, at higher risk thresholds (>0.5), when it came to predict an event,
366 the dengue score displayed a better sensitivity (in other words, higher TP rate, or a lower cost of FN
367 *versus* FP cost). Taken together with respect to the SARS-CoV-2 strategy of testing, isolating, and
368 tracing, our findings encourage evaluating the addition of clinical or biological discriminative
369 variables [38,39] in the COVID-19 score to improve its sensitivity across the risk thresholds while in
370 regard to the dengue strategy of testing, isolating, and targeted vector control, they encourage the

371 fitting with more specific epidemiological variables highly predictive of an infective bite by an *Aedes*
372 mosquito.

373 At an individual risk level, predictions should be guided using first of all calibration
374 performances (calibration plots and goodness-of-fit metrics) [24]. Our findings showed that the
375 calibration of the models (Table S6 to S8) and their derived scores (Table S9) were excellent and
376 consensual for dengue which enables individual risk prediction and satisfactory for COVID-19 which
377 suggests caution for individual risk prediction.

378

379 **Generalizability**

380 The COVIDENGUE scores were developed from data acquired within a hospital-based SARS-CoV-2
381 testing center on Reunion Island which is a tropical setting where dengue co-circulated early on
382 during the first pandemic wave at a time when there was no possibility to screen for COVID-19
383 outside the hospital. The circulation of the SARS-CoV-2 variant was furthermore unknown and the
384 population of infected people were mainly composed of relatively healthy travelers [9,35]. Thus,
385 although our center served an ambulatory healthcare driven population, the scores will have to be
386 validated in primary care settings before being broadly used in the community. They will also have to
387 be validated in the highly comorbid autochthonous population of the island [9,35].

388 In future research, the scores should be studied in the context of newly circulating SARS-CoV-2
389 variants as well as in the context of populations immunized against dengue or COVID-19. On Reunion
390 Island, the first wave of SARS-CoV-2 circulation ended in June 2020 as a result of the influence of the
391 first national lockdown. The second wave began in August 2020 during the winter season of the
392 region and was concomitant to the spread of the D614G mutation in Europe [7]. Since this period,
393 SARS-CoV-2 transmission has been mainly autochthonous and successively maintained through the
394 circulation of both South African (B.1.351/501Y.V2) and the Indian (B.1.617/21APR-02) variants of
395 concerns (VOCs). While the clinical presentation of dengue appears to be different between DENV-2
396 and DENV-1 serotype infections (DENV-1 has been predominant on the island since 2020) on top of

397 the proportions of secondary infections [41], it is not yet clear whether the prevalence of COVID-19
398 has changed throughout the circulating VOCs despite a trend towards increased severity reported
399 with the UK (B.1.1.7/501Y.V1) [42], along with the Brazilian (P.1/501Y.V3) [43], South African [44], or
400 Indian variants [45]. The same could be said to the potential for more clinically apparent
401 manifestations of COVID-19 when DENV infection precedes SARS-CoV-2 infection [36] as well as the
402 potential for higher severity with SARS-CoV-2 DENV co-infections [2]. Both have to be fully
403 investigated in the future with the diagnostic value of the COVIDENGUE scores evaluated.
404
405 **Implications**
406 For individual risk prediction and clinical practice, the equations of estimated probability of being
407 diagnosed as infected derived from the scores could be used to define individual risks conditional to
408 adequate calibration. Herein, we have shown that the COVIDENGUE scores could be useful to
409 diagnose dengue patients in a tropical SARS-CoV-2 screening center, however they deserved further
410 improvements for diagnosing COVID-19.
411 For public health purposes, the score values could be incorporated into testing strategies and
412 guided with mitigation interventions whenever routine biological testing is ineffective. For clinical
413 research, the cut-off values could serve to risk stratification in new diagnostic studies and the
414 COVIDENGUE scores items incorporated into propensity scores. For benchmarking of prediction
415 models, the predicted risk probabilities of a new model could also be summed up and compared to
416 the total number of infected individuals (to define risk thresholds) under the assumption that such an
417 observed-to-predicted risk ratio together with the slope of the calibration plots and the Hosmer-
418 Lemeshow chi2 test probability, would be close to one, to underlie the adequate calibration of the
419 new model.
420 When it comes to testing the external validity of the COVIDENGUE scores in a different
421 epidemiological context, or to improving their predictive performances by adding or removing
422 variables within a new model, investigators will have to consider using calibration plots and

423 goodness-of-fit statistics to see whether the model is properly calibrated and could apply to
424 individual risk prediction. Such novel investigations should delve deeper into demonstrating the
425 clinical use while providing new indicators such as the IDI (Integrated Discrimination Improvement)
426 and/or the net benefit from classification plots or decision curve analyses [13,14].
427
428 **Conclusions**
429 In conclusion, the COVIDENGUE scores proved discriminant to differentiate COVID-19 and dengue
430 from OFIs in the context of SARS-CoV-2 testing center during a co-epidemic. Further studies are
431 needed to validate or refine these scores in other settings.
432
433 **Acknowledgments**
434 The authors are indebted to the staffs of the Department of Infectious Diseases and Tropical
435 Medicine, especially Dr Yatrika Koumar, and the SARS-CoV-2 testing center with special appreciation
436 given to Dr Antoine Joubert and the nurses who performed the questionnaires. The authors would
437 also like to thank the biologists at CHU de La Réunion for their timely diagnosis, the participants for
438 their interest in research and AcaciaTools for their reviewing and medical writing services.

Supporting information

Supplementary material is available online. While the supplementary tables have been copyedited, the methodological appendix and the Venn diagram have not been copyedited and are the sole responsibility of the authors. Questions and comments about these should be addressed to the corresponding author. STROBE and TRIPOD checklists (text file S2).

Notes

Author's contributions.

Conceptualization: Fanny Andry, Patrick Gérardin, Cécile Levin. Data curation: Patrick Gérardin. Formal analysis: Patrick Gérardin, Antoine Bertolotti, Olivier Maillard, Léa Bruneau, Cécile Levin. Investigation: Frédéric Accot, Florian Legrand, Patrice Poubeau, Rodolphe Manaquin, Fanny Andry, Antoine Bertolotti, Cécile Levin. Methodology: Patrick Gérardin. Project administration: Fanny Andry. Resources: Cécile Levin. Software: Patrick Gérardin. Supervision: Olivier Maillard, Antoine Bertolotti. Validation: Patrick Gérardin, Cécile Levin. Visualization: Patrick Gérardin. Writing – original draft: Patrick Gérardin. Writing – review & editing: Patrick Gérardin, Olivier Maillard, Léa Bruneau, Frédéric Accot, Florian Legrand, Patrice Poubeau, Rodolphe Manaquin, Fanny Andry, Antoine Bertolotti and Cécile Levin.

List of abbreviations (alphabetic order)

aOR: Adjusted odds ratio

AUC: Area under receiver operating characteristic curve

CIR: Cumulative incidence rate (attack rate)

CNR: *Centre national de reference*

COVID-19: Coronavirus 2019

DENV: Dengue virus

ICU: Intensive Care Unit

MHL test: Multinomial Hosmer-Lemeshow test

MLR: Multinomial logistic regression

OFIs: Other febrile illnesses

RT-PCR: Reverse transcription – polymerase chain reaction

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

SpO2: Pulse oxymetry

UDACS: *Unite de dépistage ambulatoire du coronavirus sud*

URTI: Upper respiratory tract infection

VOCs: variants of concerns

95% CI: 95% confidence interval

Funding: None

Potential conflicts of interest: All authors would like to report that there are no conflicts of interest in relation to this research. All authors have signed the ICMJE disclosure form for potential conflicts of interest.

Data availability statement: Data are entirely accessible through a data repository through the publication of this article.

References

1. Caron M, Paupy C, Grard G, Becquart P, Mombo I, Nso BB, et al. Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa. Clin Infect Dis 2012; 55: e45-53. http://dx.doi:10.1093/cid/cis530. Epub 2012 Jun 5.

2. Mejia-Parra JL, Aguilar-Martinez S, Fernandez-Mogollon JL, Luna C, Bonilla-Aldana DK, Rodriguez-Morales AJ, et al. Characteristics of patients coinfected with Severe Acute Respiratory Syndrome Coronavirus 2 and dengue virus, Lambayeque, Peru, May–August 2020: A retrospective analysis. Travel Med Infect Dis 2021; 43: 102132. https://dx.doi/10.1016/j.tmaid.2021.102132. Epub 2021 Jun 26.

3. Huang SY, Lee IK, Wang L, Liu JW, Hung SC, Chen CC, et al. Use of simple clinical and laboratory predictors to differentiate influenza from dengue and other febrile illnesses in the emergency room. BMC Infect Dis 2014; 14: 623. http://dx.doi:10.1186/s12879-014-0623-z.

4. Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, Gubler DJ. Preventing dengue epidemics during COVID-19 pandemic. Am J Trop Med Hyg 2020; 103: 570-571. http://dx.doi: 10.4269/ajtmh.20-0480.

5. Gérardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, et al. Estimating Chikungunya prevalence in La Réunion island outbreak by serosurveys: two methods for two critical times of the epidemic BMC Infect Dis 2008; 8: 99. http://dx.doi:10.1186/1471-2334-8-99.

6. Vincent M, Larrieu S, Vilain P, Etienne A, Solet JL, François C, et al. From the threat to the large outbreak: dengue on Reunion island. Euro Surveill 2019; 24: 1900346. http://dx.doi: 10.2807/1560-7917.ES.2019.24.47.1900346.

7. Wilkinson DA, Lebarbenchon C, Atyame C, Hafsia S, Jaffar-Bandjee MC, Menudier-Yemandja L, et al. Genomic insights into early SARS-CoV-2 strains isolated in Reunion Island. MedRxiv 2021 Jan 6. https://doi.org/10.1101/2021.01.21.21249623.

8. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ 2020;369:m1328. https://dx.doi.org/10.1136/bmj.m1328.

9. Joubert A, Andry F, Bertolotti A, Accot F, Koumar Y, Legrand F, et al. Distinguishing non severe cases of dengue from COVID-19 in the context of co-epidemics: a cohort study in

a SARS-CoV-2 testing center on Reunion island. PLoS Negl Trop Dis 2021; 15: e0008879. https://dx.doi/10.1371/journal.pntd.8879.

10. Leening MJG, Steyerberg EW, Van Calster B, D'Agostino RB, Pencina MJ. Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and a model perspective. Stat Med 2014; 33: 3415-8. https://dx.doi/10.1002/sim.6133.

11. Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. New Engl J Med 2020; 382; e76. https://dx.doi/10.1056/NEJMvcm2010260.

12. Fagerland MW, Hosmer DW. A generalized Hosmer-Lemeshow goodness-of-fit test for multinomial logistic regression models. Stata Journal 2012; 12: 447-53. https://dx.doi/10.1177/1536867X1201200307.

13. Verbackel JY, Steyerberg EW, Uno H, De Cock B, Wynants L, Collins GS, et al. ROC curves for clinical prediction models part 1. ROC plots showed no added value to the AUC when evaluating the performance of clinical prediction models. J Clin Epidemiol 2020; 126: 207-15. https://dx.doi/10.1016/j.clinepi.2020.01.028.

14. Van Calster B, Wynants L, Collins GS, Verbackel JY, Steyerberg EW. ROC curves for clinical prediction models part 3. The ROC plot: a picture that needs a 1000 words. J Clin Epidemiol 2020; 126: 220-3. https://dx.doi/10.1016/j.clinepi.2020.05.037.

15. Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration hierarchy for risk models was defined: from utopia to empirical data. Stat Med 2016; 74: 167-76. https://dx.doi/10.1016/j.jclinepi.2015.12.005.

16. Lemeshow S, Hosmer DW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982; 115: 92–8. https://dx.doi/10.1093/oxfordjournals.aje.a113284.

17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)

543 statement: guidelines for reporting observational studies. PLoS Med 2007; 4: e296.
544 https://dx.doi/10.1371/journal.pmed.0040296.
545 18. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable
546 prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC
547 Med 2015; 13: 1. https://dx.doi/10.1186/s12916-014-0241-z.
548 19. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the
549 paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre
550 study. Lancet 2003; 362: 192-7. https://dx.doi/10.1016/S0140-6736(03)13908-6.
551 20. Nowak MD, Sordillo EM, Gitman MR, Paniz-Mondolfi AE. Coinfection in SARS-CoV-2 infected
552 patients: Where are influenza virus and rhinovirus/enterovirus? J Med Virol 2020; 92: 1699-
553 1700. https://dx.doi/10.1002/jmv.25953. Epub 2020 Jul 17.
554 21. Jin-Jung Y, Campèse C, Lévy-Bruhl D, Savitch Y; Santé Publique France. Grippe: bilan de la saison
555 2019-2020. Chêne G ed: 2020 Oct 13; 10: 1-10. https://www.santepubliquefrance.fr/maladies-
556 et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-
557 national/bulletin-epidemiologique-grippe.-bilan-de-la-surveillance-saison-2019-2020.
558 22. Lokida D, Lukman N, Salim G, Butar-butar DP, Kosasih H, Wulan WN, et al. Diagnosis of COVID-19
559 in a dengue-endemic area. Am J Trop Med Hyg. 2020; 10: 1220-2. https://dx.doi/
560 10.4269/ajtmh.20-0676.
561 23. Vanroye F, Van den Bossche D, Brosius I, Tack B, Van Esbroek M, Jacobs J. COVID-19 antibody
562 detecting rapid diagnostic tests show high cross-reactivity when challenged with pre-pandemic
563 malaria, schistosomiasis and dengue samples. Diagnostics (Basel) 2021; 11: 1163. https://dx.doi/
564 10.3390/diagnostics11071163.
565 24. Khandker SS, Nik Hashim NHH, Deris ZZ, Shueb RH, Islam MA. Diagnostic accuracy of rapid
566 antigen test kits for detecting SARS-CoV-2: a systematic review and meta-analysis of 17,171
567 suspected COVID-19 patients. J Clin Med 2021; 10: 3493. https://dx.doi/10.3390/jcm10163493.

568 25. Van Calster B, Steyerberg EW, Harrell FH. Risk prediction for individuals. JAMA 2015; 314: 1875.
569 https://dx.doi/10.1001/jama.2015.12215.
570 26. Van Calster B, Vergouwe Y, Looman CWN, Van Belle V, Timmerman D, Steyerberg EW. Assessing
571 the discriminative ability of risk models for more than two outcome categories. Eur J Epidemiol
572 2012; 27: 761–70. https://dx.doi/10.1007/s10654-012-9733-3.
573 27. Van Hoorde K, Vergouwe Y, Timmerman D, Van Huffel S, Steyerberg EW, Van Calster B.
574 Assessing calibration of multinomial risk prediction models. Stat Med 2014; 33: 2585-96.
575 https://dx.doi/10.1002/sim.6114.
576 28. Usman MS, Siddiqi TJ, Khan MS, Patel UK, Shahid I, Ahmed J, et al. Is there a smoker's paradox in
577 COVID-19? BMJ Evid Based Med. 2020 Aug 11:bmjebm-2020-111492.
578 https://dx.doi/10.1136/bmjebm-2020-111492. Online ahead of print.
579 29. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, COVID-19 Systematic Urgent Review
580 Group Effort (SURGE) Study Authors. Physical distancing, face masks, and eye protection to
581 prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and
582 meta-analysis. Lancet 2020; 395: 1973-87. https://dx.doi/0.1016/S0140-6736(20)31142-9. Epub
583 2020 Jun 1.
584 30. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM et al. Occurrence and
585 transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: A living
586 systematic review and meta-analysis. PLoS Med. 2020; 17: e1003346. https://dx.doi/
587 10.1371/journal.pmed.1003346. eCollection 2020 Sep.
588 31. Premaratna R, Pathmeswaran A, Amarasekara NDDM, Motha MBC, Perera KVHKK, de Silva HJ. A
589 clinical guide for early detection of dengue fever and timing of investigations to detect patients
590 likely to develop complications. Trans R Soc Trop Med Hyg 2009;103: 127-31. https://dx.doi/10.
591 1016/j.trstmh.2008.07.024.
592 32. Riddell A, Babiker ZO. Imported dengue fever in East London: a 6-year retrospective
593 observational study. J Travel Med 2017; 24: 1-6. https://dx.doi/10.1093/jtm/tax015.

594 33. El-Anwar MW, Eesa M, Mansour W, Zake LG, Hendawy E. Analysis of Ear, Nose and Throat
595 Manifestations in COVID-19 Patients. Int Arch Otorhinolaryngol. 2021; 25: e343-e348.
596 https://dx.doi/10.1055/s-0041-1730456.
597 34. Gu W, Deng X, Reyes K, Hsu E, Wang C, Sotomayor-Gonzalez A, et al. Associations of early
598 COVID-19 cases in San Francisco with domestic and international travel. Clin Infect Dis 2020; 71:
599 2976-80. https://dx.doi/10.1093/cid/ciaa599.
600 35. Krol P, Coolen-Allou N, Teysseyre L, Traversier N, Beasley F, Nativel M, et al. Differential
601 diagnoses of severe COVID-19 in tropical areas: the experience of Reunion Island. Trop Med Int
602 Health 2021; 26: 444-52. https://dx.doi/10.1111/tmi.13542.
603 36. Nicolete VC, Rodrigues PT, Johansen IC, Corder RM, Tonini J, Cardoso MA et al. Interacting
604 epidemics in Amazonian Brazil: prior dengue infection associated with increased COVID-19 risk
605 in a population-based cohort study. Clin Infect Dis 2021; ciab410.
606 https://dx.doi/10.1093/cid/ciab410. Online ahead of print.
607 37. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2
608 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with
609 Bayesian analyses (version 7). Addiction 2021; 116: 1319-68. https://dx.doi/10.1111/add.15276.
610 Epub 2020 Nov 17.
611 38. Romero-Gameros CA, Colin-Martínez T, Waizel-Haiat S, Vargas-Ortega G, Ferat-Osorio E,
612 Guerrero-Paz JA, et al. Diagnostic accuracy of symptoms as a diagnostic tool for SARS-CoV 2
613 infection: a cross-sectional study in a cohort of 2,173 patients. BMC Infect Dis. 2021; 21: 255.
614 https://dx.doi/10.1186/s12879-021-05930-1.
615 39. Rosso F, Parra-Lara LG, Agudelo-Rojas OL, Martinez-Ruiz DM. Differentiating dengue from
616 COVID-19: comparison of cases in Colombia. Am J Trop Med Hyg 2021; tpmd200912.
617 https://dx.doi/10.4269/ajtmh.20-0912. Online ahead of print.

618 40. Ruiy W, Hsu SY, Tsai HL, CT Chen. COVID-19 mimicking dengue fever with the initial
619 manifestation of retro-orbital pain – a rare case. J Formos Med Assoc 2020; 119: 1715-16.
620 https://dx.doi/10.1016/j.jfma.2020.05.039. Epub 2020 Jun 4.
621 41. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Haldstead SB. Dengue infection. Nat Rev Dis
622 Primers 2016; 2: 16055. https://dx.doi/10.1038/nrdp.2016.55.
623 42. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality
624 in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ
625 2021; 372: n579. https://dx.doi/10.1136/bmj.n579.
626 43. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DdS, Mishra S, et al. Genomics and
627 epidemiology of the P1.SARS-CoV-2 lineage in Manaus, Brazil. Science 2021; 372(6544): 815-21.
628 https://dx.doi/10.1126/science.abh.2644. Epub 2021 Apr 14.
629 44. Puech B, Legrand A, Simon O, Combe C, Jaffar-Bandjee MC, Caron M, et al. Prognosis of
630 critically-ill patients with acute respiratory failure due to SARS-CoV-2 (501Y.V2) variant: a
631 multicenter retrospective matched cohort study. Research Square 2021. https://dx.doi/
632 10.21203/rs.3.rs-80608v2.
633 45. Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPHS, et al. Clinical and virological features of
634 SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315
635 (Beta), and B.1.617.2 (Delta). Clin Infect Dis 2021; ciab721. https://dx.doi/
636 10.1093/cid/ciab721. Online ahead of print.

Table 1. Final best fit multinomial logistic regression model distinguishing the independent predictors of COVID-19 and dengue from those of other febrile illnesses among 969 participants who consulted at a COVID-19 screening center in Saint Pierre (Reunion Island) during the COVID-19 dengue co-epidemics from 23 March to 10 May 2020

Outcomes (versus other febrile illnesses as controls*)	COVID-19 (N = 73)					Dengue (N = 60)				
Predictors	**n**	**CIR, (%)**	**aOR**	**95% CI**	**Points**	**n**	**CIR, (%)**	**aOR**	**95% CI**	**Points**
Contact with a COVID-19 positive case	40	15.38	**4.26**	**2.33 to 7.78**	**+ 3**	6	2.31	0.71	0.26 to 1.87	0
Return from travel abroad < 15 days	38	16.03	**3.53**	**2.05 to 6.05**	**+ 3**	6	2.53	0.41	0.15 to 1.05	- 1
Previous individual episode of dengue	4	9.06	2.16	0.56 to 8.29	+ 1	9	20.45	**4.50**	**1.68 to 12.00**	**+ 3**
Active smoker †	4	2.53	**0.25**	**0.09 to 0.67**	**- 3**	12	7.59	1.38	0.65 to 2.91	0
Cough	32	6.82	0.95	0.53 to 1.68	0	17	3.62	**0.36**	**0.18 to 0.70**	**- 2**
Body ache ‡	29	7.09	1.26	0.70 to 2.24	0	52	12.71	**6.35**	**2.56 to 15.71**	**+ 5**
Anosmia	26	27.96	**7.64**	**4.13 to 14.12**	**+ 7**	3	3.23	0.47	0.11 to 2.01	- 1
Headache	28	5.70	0.92	0.54 to 1.55	0	55	11.20	**5.51**	**1.85 to 16.41**	**+ 5**
Retro-orbital pain	1	2.27	0.53	0.06 to 4.53	- 1	17	38.64	**4.42**	**2.03 to 9.59**	**+ 5**
Upper respiratory tract infection symptoms #	28	5.63	0.53	**0.31 to 0.90**	**- 1**	20	4.02	**0.51**	**0.26 to 0.98**	**- 1**
Presentation > 3 days after symptom onset	53	9.55	1.71	0.94 to 3.10	+ 1	24	4.32	0.75	0.39 to 1.42	0

Multinomial logistic regression model with other non COVID-19 non dengue febrile illnesses*, taken as controls. Data are numbers, cumulative incidence rates (CIR) expressed as percentages, adjusted odd ratios (aOR), 95% confidence intervals (95% CI). † Current smoker, as compared to never smoker and past smoker; ‡ muscle pain or backache with tightness and/or stiffness; # sore throat, runny nose, nasal congestion, or sneezing. 44 Participants with missing data excluded from the model (1013-969) of whom 42 had missing information on the delay of presentation, 1 on the return from travel abroad, 1 on a previous episode of dengue. The indicators of performance of the model are as follows: Bayesian information criterion -5709, Goodness of fit chi-2 test's probability 0.31, areas under the receiver operating characteristic curves 0.80 (95%CI 0.74-0.86) and 0.89 (95%CI 0.84-0.92), respectively. For COVID-19 prediction, the estimated probability of being infected is $Prob_{(Y=1/x)} = 1 / (1 + \exp^{-(-3.82 + \sum \beta_i \times X_j)})$ and the beta coefficients of the model are as follows: $\sum \beta_i \times X_j = 1.45\ X_1 + 1.26\ X_2 + 0.77\ X_3 - 1.37\ X_4 - 0.05\ X_5 + 0.23\ X_6 + 2.03\ X_7 - 0.08\ X_8 - 0.63\ X_9 - 0.64 X_{10} + 0.54\ X_{11}$ and intercept coefficient is - 3.82. For dengue prediction, the estimated probability of being infected is $Prob_{(Y=1/x)} = 1 / (1 + \exp^{-(-4.40 + \sum \beta_i \times X_j)})$ and the beta coefficients of the model are as follows: $\sum \beta i \times Xj = -0.35\ X_1 - 0.90\ X_2 + 1.50\ X_3 + 0.32\ X_4 - 1.02\ X_5 + 1.85\ X_6 - 0.75\ X_7 + 1.71\ X_8 + 1.49\ X_9 - 0.66\ X_{10} - 0.29\ X_{11}$ and intercept coefficient is - 4.40.

Figures



Figure 1. Study population for differentiating dengue and COVID-19 from other febrile illnesses in co-epidemics



Figure 2. Discriminative ability of the final model and of COVIDENGUE scores for COVID-19 and dengue at Saint-Pierre, Reunion Island from 23 March to 10 May 2020

Notes: Areas under receiver operating characteristic (AUC) curves are given for the best fit compromise final models (reference models) and the COVIDENGUE scores before validation by bootstrapping. The better the model or the score discriminates, the more the ROC curve approaches the upper left corner of the plot. A model with no discriminative ability has a true ROC curve that lies on the diagonal line.



Figure 3. Diagnostic performances of the COVIDENGUE scores


Subjects presenting at the COVID-19 screening center
1,715
Incoming patients screened opportunistically
370
Outpatients screened for COVID-19 compatible symptoms or contact
1,345
Fully asymptomatic subjects
332
Symptomatic subjects eligible to the analysis
1,013
Non COVID-19 non dengue other febrile illnesses (controls)
872
COVID-19 confirmed cases
80
Dengue confirmed cases
61


(a)
COVID-19 model
Dengue model
AUC 0.80, 95%CI 0.74 - 0.86
AUC 0.89, 95%CI 0.84 - 0.92
Sensitivity (%)
100 – Specificity (%)
(b)
COVID-19 model
COVID score
AUC 0.80, 95%CI 0.74 - 0.86
AUC 0.79, 95%CI 0.76 - 0.82
Sensitivity (%)
100 – Specificity (%)
(c)
Dengue model
Dengue score
AUC 0.89, 95%CI 0.84 - 0.92
AUC 0.88, 95%CI 0.85 - 0.90
Sensitivity (%)
100 – Specificity (%)
(d)
COVID score
Dengue score
6
3
3
0
10
11
AUC 0.79, 95%CI 0.76 - 0.82
AUC 0.88, 95%CI 0.85 - 0.90
Sensitivity (%)
100 – Specificity (%)


(a)
Sensitivity (%)
COVID-19
dengue
(b)
Specificity (%)
COVID-19
dengue
(c)
Positive predictive value (%)
COVID-19
dengue
(d)
Negative predictive value (%)
COVID-19
dengue
0 10 20 30 40 50 60 70 80 90 100
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18